Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech.

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $24.42, marking a -5.48% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.52% for ...

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $25.11, demonstrating a -8.26% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a ...

Viking Therapeutics has seen its share price move sharply over recent years, and the recent pullback puts fresh focus on whether that journey still lines up with what its balance sheet can support.

Viking Therapeutics faces dilution risk, rising costs, and tough obesity drug competition. Read here for a detailed analysis ...

View original content to download multimedia: ...

In a report released yesterday, Edward Nash from Canaccord Genuity maintained a Buy rating on Viking Therapeutics, with a price target of $114.00. The company’s shares closed yesterday at $25.47.

Jaguar Health plunges 59% on apparent profit-taking with no verified catalyst, while Viking Therapeutics sheds 4% cooling off after positive obesity trial news. With IBB nearly flat and SPY down 0.6%, ...

Viking Therapeutics (VKTX) just posted third quarter results that widened its net loss, as spending on late stage obesity ...

The drug candidate's subcutaneous results are strong, but oral formulation data is still pending. The upcoming oral maintenance trial results are crucial to VKTX's dual-formulation strategy. VK2735 is ...